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Background. In a number of investigations, hippocampal neurochemicals were evaluated in the patients with bipolar disorder who
were on their ﬁrst episode or euthymic periods. However, we did not meet any investigation in which only patients with bipolar
depression were examined. As a consequence, the objective of the present study was to examine both sides of hippocampus of
patients with bipolar disorder in depressive episode and healthy controls using 1H-MRS. Methods. Thirteen patients with DSM-IV
bipolar I disorder, most recent episode depressed, were recruited from the Department of Psychiatry at Firat University School
of Medicine. We also studied 13 healthy comparison subjects who were without any DSM-IV Axis I disorders recruited from the
hospital staﬀ. The patients and controls underwent proton magnetic resonance spectroscopy (1H-MRS) of their hippocampus.
NAA, CHO, and CRE values were measured. Results. No signiﬁcant eﬀect of diagnosis was observed for NAA/CRE ratio. For the
NAA/CHO ratio, the ANCOVA with age, gender, and whole brain volume as covariates revealed that the patients with bipolar
depression had signiﬁcantly lower ratio compared to healthy control subjects for right and for left side. As for the CHO/CRE
ratio, the diﬀerence was statistically signiﬁcant for right side, with an eﬀect diagnosis of F = 4.763, P = 0.038, and was very nearly
signiﬁcant for left side, with an eﬀect diagnosis of F = 3.732, P = 0.064. Conclusions. We found that the patients with bipolar
depression had lower NAA/CHO and higher CHO/CRE ratios compared to those of healthy control subjects. The ﬁndings of the




and Statistical Manual of Mental Disorders Fourth Version
(DSM-IV) characterized by at least one manic or mixed
episode. Although the existence of depressive episodes is not
required, these type of episodes frequently occurred in bipo-
lar I disorder. Neurobiological factors have been implicated
in the pathogenesis of bipolar I disorder, as in other psy-
chiatric disorders. Recently, a huge number of neuroimaging
investigations have been performed in patients with various
psychiatric disorders to identify morphometric changes in
speciﬁc brain areas. These techniques are noninvasive ones
that provide our best understanding of the connection
between the clinical features and related neurobiology in
psychiatric disorders including bipolar I disorder. Thus, in
patientswithbipolardisorder,manyinvestigationshavebeen
performed and have revealed some important ﬁndings such
as decreased subgenual prefrontal cortex volume, decreased
prefrontal gray matter, and amygdala volume increase [1–5].
On the other hand, increased white matter hyperintensities
and decreased cerebellar areas have been reported [6, 7].
Our group also carried out some structural investigations in
diﬀerent regions of brains of bipolar patients. We performed
a volumetric MRI study to assess the subregions of the
cingulate gyrus: left anterior cingulate (LAC), left posterior
cingulate (LPC), right anterior cingulate (RAC), and right
posterior cingulate (RPC) in bipolar patients that were either
unmedicated (n = 10), on valproate monotherapy (n = 10)
or on valproate plus quetiapine (n = 10) versus healthy
comparisons (n = 10). In that study, we found that drug-
free patients had signiﬁcantly smaller LAC and LPC volumes2 Depression Research and Treatment
compared with valproate and valproate plus quetiapine
groups and healthy controls, with a trend toward signiﬁcant
diﬀerence between valproate plus quetiapine group and val-
proate group in regard to only LAC in post hoc comparisons
and concluded that valproate and quetiapine might have
neuroprotective eﬀects [8]. In our another previous struc-
tural MRI investigation, we investigated the corpus callosum
(CC) areas by MRI in 12 ﬁrst-episode patients with bipolar
disorder and 12 controls. We found that bipolar patients
had signiﬁcantly smaller areas of total CC, anterior body
posterior body, and isthmus compared with healthy control
subjects by ANCOVA, with age, gender, and intracranial
volume (ICV) as covariates and that there was a negative
correlation between total CC, posterior body and isthmus
areas, and Young Mania Rating Scale (YMRS) scores, and
suggested that the ﬁndings suggest that CC morphology may
be associated with the pathophysiology of bipolar disorder
[9]. As for the functional neuroimaging investigations in
bipolar disorder, the published studies alterations in glucose
metabolism, regional cerebral blood ﬂow or high-energy
phosphate metabolism in patients with bipolar disorder in
the prefrontal and temporal cortex, basal ganglia and amyg-
dala [1, 10]. Previously, we performed two-proton magnetic
resonance spectroscopy (1H MRS) investigations in bipolar
disorder. We ﬁrst evaluated NAA values in patients with
ﬁrst-episode bipolar disorder and found statistical analysis
to reveal a signiﬁcant eﬀect of diagnosis for NAA/CRE and
for NAA/CHO but not for CHO/CRE and concluded that
hippocampal neuronal abnormalities might be present at the
onset of bipolar I disorder and might be associated with
the severity of bipolar I disorder [11]. In our other NAA
investigation, we examined the eﬀects of mood stabilizer
alone and the combination of mood stabilizer and atypical
antipsychotic, quetiapine, on hippocampal neurochemical
markers of thirty bipolar disordered patients [12]; ten were
ﬁrst applied patients who never had taken any drug for this
condition (drug-free group), ten were on ongoing valproate
treatment (valproate group), and the rest were on val-
proate plus quetiapine treatment (valproate plus quetiapine
group). We found that drug-free patients had signiﬁcantly
lower NAA/CRE and NAA/CHO ratios compared with
valproate and valproate plus quetiapine groups and healthy
controls, with a signiﬁcant diﬀerence between valproate
plus quetiapine group and valproate group in regard to
only NAA/CHO in post hoc comparisons. Proton magnetic
resonance spectroscopy (1H-MRS), an increasing trend in
psychiatric investigation, allows biochemical constituents
to be directly assayed in vivo, such as choline-containing
compounds (CHO), an index of membrane metabolism,
creatine + phosphocreatine (CRE), involved in cell energetic
metabolism and n-acetyl-containing compounds (especially
N-acetylaspartate—NAA). While CHO and CRE are present
in neurons and in glial cells, NAA is found primarily in
neurons [13] and in highest concentrations in pyramidal
glutamatergic neurons [14]. NAA, a representative marker
of neuronal structural integrity, seems sensitive to mito-
chondrial oxidative phosphorylation and it may correlate
highly with tissue glutamate levels [15, 16]. Low NAA is
thought to represent loss of neurons and/or axons, reduction
of interneuronal neuropil, and neuronal or axonal metabolic
dysfunction or damage [17, 18]. 1H MRS studies concerning
bipolar disorder focused on dorsolateral prefrontal cortex
(DLPFC)andhippocampalregions.A 1HMRSstudyshowed
signiﬁcant reductions of NAA peaks in the DLPFC of adult
bipolar disorder subjects [19], whereas two other MRS
studies [20, 21] did not ﬁnd any diﬀerences in DLPFC
or frontal lobes. Chang et al. [22] reported reduced NAA
levels in DLPFC in a sample of pediatric bipolar patients
who had a parent with bipolar disorder. Furthermore,
there is extensive literature from functional imaging and
postmortem studies in support of DLPFC dysfunction in
bipolar disorder [23, 24]. Studies using high-resolution MRS
reveal that unmedicated patients with bipolar disorder have
decreased levels bilaterally of NAA in the hippocampus
[21], as compared with healthy control subjects. Moreover,
therapeutic doses of lithium reverse these decreased levels of
NAA in their brain [25]. Deicken et al. [26]f o u n dl o wN A A
bilaterally in the absence of smaller hippocampal volume
as measured by MRI, supporting the idea that NAA might
be a more sensitive marker of neuronal damage or loss
than quantitative MRI measurements of tissue loss. In a
numberofinvestigations,hipopcampalneurochemicalswere
evaluated in the patients with bipolar disorder who were on
their ﬁrst episode or euthymic periods. However, we did not
meet any investigation in which only patients with bipolar
depressionwereexamined.Asaconsequence,theobjectiveof
the present study was to examine both sides of hippocampus
of patients with bipolar disorder in depressive episode and
healthy controls using 1H-MRS.
2. Methods
2.1. Subjects and Clinical Evaluation. Sixteen patients with
DSM-IV bipolar I disorder, most recent episode depressed
who suﬀered from MRI for diﬀerential diagnosis, were
recruited from Department of Psychiatry at Firat University
School of Medicine. We also studied 16 healthy comparison
subjects who were without any DSM-IV Axis I disorders
recruited from the hospital staﬀ. All subjects participated
afterreviewingandsigningtheconsentform.TheDiagnostic
and Statistical Manual of Mental Disorders Fourth Version
(DSM-IV) diagnoses were obtained using Turkish version of
Structured Clinical Interview for DSM-IV (SCID) [27].
Exclusion criteria were the presence of any comorbid
psychiatric disorder, current serious medical problems, or
alcohol/substance abuse within the 6 months preceding
the study. Of the patients, two had borderline personality
disorder, one had obsessive compulsive personality disorder,
and one had dependent personality traits. Healthy control
subjects had no DSM-IV Axis I disorders in self or in a ﬁrst-
degree relative, as determined by the SCID nonpatient ver-
sion, no current medical problems, neurologic or psychiatric
histories, and no use of psychoactive medication within 2
weeks of the study.
The severity of depression and manic symptoms was
evaluated by using the Hamilton Depression rating Scale
(HDRS) [28] and Young Mania Rating Scale (YMRS) [29],
respectively.Depression Research and Treatment 3
Figure 1: Position of hippocampal voxels and sample magnetic
resonance spectrum.
2.2. MRI Procedure. Multiple-slice 1H-MRSI was performed
on a conventional GE-SIGNA 1.5-Tesla MR imaging sys-
tem (GE Medical Systems Milwaukee, WI). A high-
resolution structural image of the entire brain was obtained
using sagittally acquired 3D spiral fast spin echo high-
resolution images (repetition time (TR) = 2000ms, echo
time (TE) = 15.6ms, ﬁeld of view (FOV) = 240mm, ﬂip
angle = 20◦, bandwidth = 20.8, slice thickness = 2.4mm,
echo spacing = 15.6ms, 8 echoes, matrix size = 240, res-
olution = 0.9375 × 0.9375 × 2.4mm). The hippocampal
region was drawn with reference to standard anatomic
atlas [30]. Anatomic measurements were obtained on a
computer advanced workstation with the GE Volume Viewer
voxtool 4.2 program. Each voxel had nominal dimensions of
10mm × 10mm × 2.4mm (0.24mL) with an actual volume
of 0.4mL, based on full width at half maximum (FWHM).
In the present study, as neurochemicals, it was examined
NAA, CRE, and CHO. The peak levels for these neurochem-
icals were detected automatically for all voxels. The signal
strength around the NAA, CHO, and CRE signal positions
was integrated to produce three 18 × 18 arrays of metabolite
signals. Position of hippocampal voxels and sample magnetic
resonance spectrum are presented in Figure 1. Meanwhile,
to minimize errors caused by changes in magnetic ﬁeld
homogeneityandtissuevolume,CREsignalsweredesignated
as the reference, with the results presented as metabolite
NAA CHO to CRE ratio. On the other hand, to account for
possible alterations in the CRE peak as an internal reference,
NAA metabolite measurements are additionally reported as
NAA/CHO ratios [31].
2.3. Statistical Analysis. Statistical analyses were conducted
using SPSS for Windows software, version 10.0 (SPSS,
Chicago, IL). Group diﬀerences in demographic variables
involving continuous data were computed using indepen-
dent t-test. Between-group comparisons involving categor-
ical data were assessed using chi-square test. All the metabo-
lite measurements were found to be normally distributed.
For each metabolite level and metabolite ratio diﬀerences
between patients and controls were tested separately by a
one-wayanalysisofcovariance(ANCOVA),withhemisphere
(left or right) as the within-group factor and diagnosis as the
between-group factor. Post hoc analyses were performed by
Tukey’s honestly signiﬁcant diﬀerence test. Correlations were
assessed with Pearson’s correlation test.
3. Results
Themaindemographicandclinicalfeaturesofthesampleare
summarized in Table 1. There were no signiﬁcant diﬀerences
between the two groups for age, whole brain volume, gray or
white matter volumes (independent sample t-test, P>0.05),
gender, or handedness (chi-square, P>0.05).
ANCOVA with age, gender, and whole brain volume as
covariates demonstrated that patients with bipolar disorder,
at most recent depressive episode, did not have diﬀerent
NAA/CRE ratio compared to that of healthy controls for
both right (eﬀect of diagnosis; F = 2.490, P = 0.127; mean
ratio; 1.38 ± 0.25 for patients and 1.26 ± 0.25 for controls)
and left sides (eﬀect of diagnosis; F = 2.326, P = 0.139;
mean ratio; 1.30 ± 0.42 for patients and 1.34 ± 0.18 for
controls)evenwhenthetwogroupswerestratiﬁedforgender
(ANCOVA with age and ICV as covariates, P>0.05). On the
other hand, no signiﬁcant eﬀect of diagnosis was observed
for NAA/CRE ratio (F = 0.073, P = 0789; mean ratio;
1.32 ± 0.25 for patients 1.29 ± 0.15 for controls). For the
NAA/CHO ratio, the ANCOVA with age, gender, and whole
brain volume as covariates revealed that the patients with
bipolar depression had signiﬁcantly lower ratio compared
to healthy control subjects for right (eﬀect of diagnosis;
F = 5.105, P = 0.032; mean ratio; 0.78 ± 0.36 for patients
and 0.94 ± 0.17 for controls) and for left sides (eﬀect of
diagnosis; F = 4.724, P = 0.043; mean ratio; 0.76 ± 0.27 for
patients and 0.97 ± 0.15 for controls). With regard to total
NAA/CHO, the patients had lower ratio (eﬀect of diagnosis;
F = 5.251, P = 0.030; mean ratio; 0.74 ± 0.21 for patients
and 0.95 ± 0.14 for controls). As for the CHO/CRE ratio,
the diﬀerence was statistically signiﬁcant for right side, with
an eﬀect diagnosis of F = 4.763, P = 0.038 (mean ratio;
1.99±0.63 for patients and 1.36±0.25 for controls), and was
very nearly signiﬁcant for left side, with an eﬀect diagnosis of
F = 3.732, P = 0.064 (mean ratio; 1.85 ± 0.84 for patients
and 1.41±0.26 for controls). With regard to total CHO/CRE
ratio, the eﬀect of diagnosis was considerable (F = 7.921,
P = 0.009, mean ratio 1.87±0.54 for patients and 1.37±0.19
for controls). Following signiﬁcant and nearly signiﬁcant
correlations were determined: NAA/CHO and YMRS (r =
0.55, P = 0.028), CHO/CRE and YMRS (r =− 0.48,
P = 0.061), NAA/CHO and age (r =− 0.70, P = 0.002),
CHO/CRE and age (r = 0.69, P = 0.003). The Pearson’s
correlationtestcouldnotreachstatisticalsigniﬁcanceforany
relation between NAA/CRE, NAA/CHO, or CHO/CRE ratio
of the hippocampus, years of education, age of onset, or total
scores of the HDRS.
4. Discussion
The main ﬁndings of the present study were as follows. (i)
No signiﬁcant eﬀect of diagnosis was observed for NAA/CRE4 Depression Research and Treatment
Table 1: Clinical and demographic information for healthy subjects and patients with bipolar depression.
Patients (n = 16) Controls (n = 16) Eﬀect of diagnosis
Age 28.1 ±3.43 0 .6 ±4.2
Gender (F/M) 4/12 6/10
Graduated from high school 12 14
Handedness (right) 16 16
Number of subjects who had family history 2 —
YMRS score 6.13 ±1.93 —
HDRS score 22.06 ±4.36 5.88 ±2.06
NAA
Right 593.63 ±412.09 838.56 ±176.19
Left 633.69 ±386.88 899.19 ±125.39
CHO
Right 793.31 ±430.69 898.88 ±139.14
Left 806.37 ±361.29 944.37 ±144.94
CRE
Right 420.63 ±253.52 669.32 ±89.81
Left 486.19 ±281.01 684.50 ±132.28
NAA/CRE 1.32 ±0.25 1.29 ±0.15 0.073
Right 1.38 ±0.25 1.26 ±0.25 2.490
Left 1.30 ±0.42 1.34 ±0.18 2.326
NAA/CHO 0.74 ±0.21 0.95 ±0.14∗ 5.251
Right 0.78 ±0.36 0.94 ±0.17∗ 5.105
Left 0.76 ±0.27 0.97 ±0.15 4.724
CHO/CRE 1.87 ±0.54 1.37 ±0.19∗∗ 7.921
Right 1.99 ±0.63 1.36 ±0.25∗ 4.763
Left 1.85 ±0.84 1.41 ±0.26∗∗∗ 3.732
Statistically signiﬁcant comparisons were indicated with an asterisk.
ICV: Intracranial volume; Y-BOCS: Yale Brown obsession compulsion scale: NAA, N-acetyl aspartate; CHO: choline; CRE: creatine.
∗P<0.05, ∗∗P<0.01, ∗∗∗P = 0.064.
ratio. (ii) For the NAA/CHO ratio, the ANCOVA with age,
gender, and whole brain volume as covariates revealed that
the patients with bipolar depression had signiﬁcantly lower
ratio compared to healthy control subjects for right and for
left side. With regard to total NAA/CHO, the patients had
lower ratio. (iii) As for the CHO/CRE ratio, the diﬀerence
was statistically signiﬁcant for right side, with an eﬀect
diagnosis of F = 4.763, P = 0.038, and was very nearly
signiﬁcant for left side, with a eﬀect diagnosis of F = 3.732,
P = 0.064. With regard to total CHO/CRE ratio, the eﬀect
of diagnosis was considerable. (iv) Following signiﬁcant and
nearly signiﬁcant correlations were determined: NAA/CHO
and YMRS (r = 0.55, P = 0.028), CHO/CRE and YMRS
(r =− 0.48, P = 0.061), NAA/CHO and age (r =− 0.70,
P = 0.002), CHO/CRE and age (r = 0.69, P = 0.003).
First of all, our ﬁndings reveal that NAA/CHO values were
lower in patients with panic disorder compared to healthy
controls for both sides of the hippocampus and there were
signiﬁcantrelationshipsbetweenNAA/CHOandYMRS(r =
0.55, P = 0.028) and NAA/CHO and age (r =− 0.70, P =
0.002) led us to consider that reduced neuronal density or
even a neurodegeneration of the hippocampal region might
exist, because NAA is considered as a measure of neuronal
integrity, as discussed in our other investigation on obsessive
compulsive disorder, another anxiety disorder [32]. On the
other hand, we previously performed two proton magnetic
resonance spectroscopy (1H MRS) investigations in bipolar
disorder. We ﬁrst evaluated NAA values in patients with
ﬁrst-episode bipolar disorder and found statistical analysis
to reveal a signiﬁcant eﬀect of diagnosis for NAA/CRE and
for NAA/CHO but not for CHO/CRE and concluded that
hippocampal neuronal abnormalities might be present at the
onset of bipolar I disorder and might be associated with
the severity of bipolar I disorder [11]. In this context, the
existence of diagnostic eﬀect for NAA/CRE and NAA/CHO
but not for CHO/CRE may suggest that changes in NAA
seem to be associated with both sides of the bipolar disorder,
that is, manic and depressive dimensions. In our another
NAA investigation on bipolar disorder, we examined the
eﬀects of valproate, a mood stabilizer, alone, and the com-
bination of valproate and atypical antipsychotic, quetiapine,
on hippocampal neurochemical markers of thirty bipolar
disordered patients [12]; ten were ﬁrst applied patients who
never had taken any drug for this condition (drug-freeDepression Research and Treatment 5
group), ten were ongoing valproate treatment (valproate
group), and the rest were on valproate plus quetiapine
treatment (valproate plus quetiapine group). We detected
that drug-free patients had signiﬁcantly lower NAA/CRE
and NAA/CHO ratios compared with valproate and val-
proate plus quetiapine groups and healthy controls, with
a signiﬁcant diﬀerence between valproate plus quetiapine
group and valproate group in regard to only NAA/CHO in
post hoc comparisons. This second investigation supports
the speculation that reduced neuronal density or even a
neurodegeneration of the hippocampal region might exist in
bipolar disoder itself, independent of its period. Moreover,
signiﬁcantly negative correlation between the NAA/CHO
ratio and age further supports the notion indicating that
there may be a neurodegenerative process. As for our
second important ﬁnding for CHO/CRE ratio, the diﬀerence
was statistically signiﬁcant for right side, with an eﬀect
diagnosis of F = 4.763, P = 0.038, and was very nearly
signiﬁcant for left side, with a eﬀect diagnosis of F =
3.732, P = 0.064. CHO is an important neurochemical in
the pathogenesis of neuropsychiatric disorders, particularly
including mood disorders. Choline is often released under
pathological conditions from its stores in cell membranes
and is therefore considered to be a marker of cellular
membrane turnover and active neurodegeneration [33, 34].
It is accepted as a metabolic marker of membrane density
and integrity, that is, phospholipid synthesis and degra-
dation [35]. Any neuropathological process leading to cell
membrane breakdown causes to release CHO and rises the
free CHO, contributing to an increased cellular membrane
turnover and active neurodegeneration [36]. At this point,
it should be mentioned that circulating corticosteroids
have an important role on the modulation of cholinergic
activity in the hippocampal region [37]. Furthermore, these
neurohormones seem to increase the vulnerability of the
septo-hippocampal cholinergic neurons to noxious insult
[38]. So, we speculate that CHO levels detected in the
patients with bipolar depression may reﬂect stress reactive
remodeling processes, as also suggested by Andrea et al. [37].
Some limitations of the present study must be ackon-
wledged. First, actually, as with all neuroimaging modalities,
the number size of the groups enrolled in a given study
tends to be small. However, it should be noted that the
small sample size is limited to make conclusive results.
Second, no control for partial volume eﬀect was another
limitation. Third, possible long-lasting eﬀects of various
medications on the hippocampus may have aﬀected our
ﬁndings. Finally, only the hippocampus was investigated in
this study; therefore we do not know exactly but it is possible
that these ﬁndings are not spesiﬁc for the hippocampus
and that this ﬁnding may be generalized to the other brain
regions as well. However, to access strong evidence, further
investigation with more patients and in multiple brain
regions is needed.
In conclusion, we found that the patients with bipolar
depression had lower NAA/CHO and higher CHO/CRE
ratios compared to those of healthy control subjects. The
ﬁndings of the present study also suggest that there may be a
degenerative process concerning the hippocampus morphol-
ogy in the patients with bipolar depression.
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